Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.84 per share. This compares to earnings of $2.77 per share a year ago.
FTSE 100 Live: Miners drag on China slowdown, PayPal jumps on bid
FTSE 100 down 23 points to 10,506 Miners fall on weaker China GDP Barratt Redrow, ICG, B&M, NextEnergy Solar publish updates 12.13pm: European stocks in...
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
After hitting fresh all-time highs last week, investors are turning their attention to JNJ's Q2 report, which is scheduled for Wednesday, July 15, before the opening bell.
JNJ Vs. KO: Which Dividend Stock Is The Better Buy?
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech.
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
JNJ is set to report second-quarter results on July 15 as investors weigh strong growth drivers, new launches and patent headwinds shaping its long-term outlook.
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate.
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them.
The five words a dividend investor never wants to hear are simple: “We just cut our dividend.
Jim Cramer: Buy the Dip on These 3 Stocks Now
A sharp sector rotation has knocked down some of the market's steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
FTSE 100 Live: AstraZeneca drags while Computacenter soars, US AI stocks gain
FTSE 100 down 10 points to 10,479 AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates 4.11pm: FTSE...
